MENU
ABOS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Acumen Pharmaceuticals (ABOS) Ownership - Who owns Acumen Pharmaceuticals?
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease... Show more
Profile
Industry
N/A
Address
427 Park Street
Phone
+1 434 297-1000
Employees
52
Web
https://www.acumenpharm.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
87.23M
P/E Ratio
N/A
Total Cash
143.37M
Projected Growth
N/A
Total Debt
30.1M
Revenue
N/A
Risk (Beta)
0.29
Dividend Yield
N/A
Total Cash/Share
2.37
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ABOS
Capitalization
87.2M
P/E Ratio
N/A
Risk (Beta)
0.29
Dividend Yield
N/A
Total Cash
143M
Total Cash/Share
2.37
Total Debt
30.1M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
117M
P/B Ratio
0.75
Cash Flow
N/A
Earnings
-2.27
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
6K
Current Ratio
5.97
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-132.35M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-59.32
Shares Held By Institutions
58.4M
Shares Outstanding - Current
60.6M
Total Liabilities
54.8M
Total Volume MTD
N/A
Value
-1
Gain YTD
-16.279
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ABOS showed earnings on August 12, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
427 Park Street
Phone
+1 434 297-1000
Employees
52
Web
https://www.acumenpharm.com